Accessibility Menu
NovelStem International logo

NovelStem International(OTC) NSTM

Current Price$0.01
Market Cap$565.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1993)-100%
5 Year-96%
1 Year-50%
1 Month+27%
NovelStem International last closing stock price
MetricPriceDate
Last closeUSD 0.012026-07-13
NovelStem International stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.85%USD 0.012026-06-25
1 month+27.33%USD 0.012026-06-09
3 month+16.94%USD 0.012026-04-13
Year to date+27.33%USD 0.012025-12-29
1 year-49.52%USD 0.022025-07-01
3 year-94.91%USD 0.232023-07-14
5 year-96.18%USD 0.302021-07-13
Since inception-99.62%USD 3.041993-11-12

NovelStem International Financials at a Glance

Market Cap

$565.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$2.53M

EPS (TTM)

$0.05

P/E Ratio

0.22

Dividend

$0.00

Beta (Volatility)

0.59 (Low)

Price

$0.01

Volume

200

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.01 - $0.04

Estimated Earnings Date

May 18, 2026

NSTM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NovelStem International

NovelStem develops technology to help doctors predict cancer drug resistance. Its main product aimed to guide treatment choices for cancer patients. The company now holds rights to future licensing income from this technology.

What’s in the NovelStem Toolbox?

  • Diagnostic Technology: Stem cell-based tests to predict if cancer drugs will work for a patient (the product generated minimal revenues before 2025; now no operating revenue).
  • Software Diagnostic Device: A software tool, approved in the European Union, that analyzes patient samples to forecast chemotherapy resistance (no current sales).
  • Media Franchise Interest: Former 50% stake in a publishing and entertainment joint venture, sold in 2025 (minimal revenue contribution).
  • Licensing Rights: Contingent right to receive future income if Hebrew University’s tech transfer office licenses out the reverted cancer diagnostic technology (currently the only asset).

NovelStem’s Growth Spurt (and Shrinkage)

  • Acquired a major stake in NewStem Ltd. (Israeli biotech) between 2018 and 2020.
  • Held 50% of NetCo Partners (media/publishing) until selling in May 2025.
  • Attempted to buy remaining NewStem shares in 2024, but lacked funding.
  • NewStem liquidated in October 2025; technology rights reverted to Yissum (Hebrew University).
  • Now focused on monetizing rights to future licensing income from Yissum.

Why NovelStem Is a Bit Different

NovelStem’s business model shifted from active biotech operations to holding a financial interest in future licensing. The company has no employees and relies on outside consultants. Its value now depends on the success of others commercializing its former technology.

Five Things You Need to Know

  • Revenue was $0 in Q3 2025, down 100% from Q3 2024.
  • Net income swung to $2.4 million in 2025, driven by asset sales and debt relief.
  • Cash at year-end 2025 was $333, with liabilities of $2.2 million.
  • All operating businesses have ceased; only asset is a right to future licensing income.
  • Accumulated deficit reached $294 million as of December 2025.

Bottom Line

NovelStem evolved from a biotech operator to a holding company with a single contingent asset. Its future depends on the commercialization of technology it no longer controls.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Ayelet Dilion-Mashiah

Website

www.novelstem.com

Headquarters

Boca Raton, FL 33431, US

NSTM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-124.80%

Return on Capital

N/A

Return on Assets

2509.19%

Earnings Yield

4.55%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$565.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

49.33M

Volume

200

Avg. Volume

5.75K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$149.13K

EBITDA

$2.72M

Operating Cash Flow

-$258.19K

Capital Expenditure

-$5.00

Free Cash Flow

-$258.19K

Cash & ST Invst.

$89.85K

Total Debt

$1.78M

NovelStem International Performance Analysis

NovelStem International annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
NovelStem International sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
NovelStem International annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.02N/A
20232023-12-31USD -0.09266.3%
20242024-12-31USD -0.07-23.4%
20252025-12-31USD 0.05N/A
NovelStem International sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-301409.1%
Q32025-09-30-103.0%
Q42025-12-31-11.8%
Q12026-03-3136.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$565.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$282.70K

N/A

Employees

2

N/A

Net Income

-$55.02K

+73.4%

EBITDA

-$4.95K

+94.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$89.85K

+2541.9%

Total Debt

$1.78M

-61.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.78M

-61.4%

Return on Assets

25.09%

N/A

Return on Invested Capital

8.50%

N/A

Free Cash Flow

-$138.73K

-217.5%

Operating Cash Flow

-$138.73K

-217.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DTRKDATATRAK International, Inc.
$0.28+0.00%
BMCSBioTech Medics, Inc.
$0.00+0.00%
MJNAMedical Marijuana, Inc.
$0.00+0.00%
ESMCEscalon Medical Corp.
$0.20+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
FFord Motor Company
$14.37+0.02%

Questions About NSTM

What is the current price of NovelStem International?

NovelStem International is trading at $0.01 per share.

What is the 52-week range for NovelStem International?

Over the past 52 weeks, NovelStem International has traded between $0.01 and $0.04.

How much debt does NovelStem International have?

As of the most recent reporting period, NovelStem International reported total debt of $1.63M.

How much cash does NovelStem International have on hand?

NovelStem International reported $89.85K in cash and cash equivalents in its most recent financial results.

What is NovelStem International’s dividend yield?

NovelStem International does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services